Activity Overview
This educational activity is an archive of the live presentation held on May 31, 2026.
For more information about this educational activity, the faculty,
and disclosures, please click here.
Target Audience
This educational activity is directed toward
hematologist-oncologists, medical oncologists, nurses, nurse practitioners,
physician assistants, and other health care providers involved in the
management of polycythemia vera (PV) and essential thrombocythemia (ET).
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Analyze recent clinical trial data and guideline updates related to treating PV and ET
- Implement evidence-based treatment strategies for both newly diagnosed and previously treated PV and ET patients
- Identify the best practices for providing supportive care and monitoring symptoms in patients with PV and ET
Gabriela Hobbs, MD
Associate Professor
Harvard Medical School
Clinical Director, Leukemia Service
Massachusetts General Hospital
Boston, MA
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Bristol Myers Squibb, Cogent, GSK, Incyte, Merck, PharmaEssentia, Sobi; Grant/Research Funding: Incyte; Ownership interests in publicly traded companies: Regeneron
Rami Komrokji, MD
Section Head, Leukemia and MDS
Vice Chair, Department of Malignant Hematology
Moffitt Cancer Center
Tampa, FL
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AbbVie, Bristol Myers Squibb, DSI, Geron, GSK, Novartis, PharmaEssentia, Rigel, Servier, Sobi, Stemline, Sumitomo Pharma, Takeda; Speakers Bureau: DSI, PharmaEssentia, Rigel, Servier, Sobi; Grant/ Research Funding: Bristol Myers Squibb
Douglas A. Tremblay, MD
Associate Professor of Medicine
Icahn School of Medicine at Mount Sinai
New York, NY
Disclosures: Advisor, Consultant, Speaker, Fee for Service Recipient: AbbVie, Cogent Biosciences, Geron, GSK, Ipsen, Pharmaessentia, Sobi; Grant/Research Funding: Blueprint, Cogent Biosciences, Geron, Oryzon, Sobi, Sumitomo
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
